使用PARP和MAPK抑制剂的组合治疗克服了晚期黑色素瘤中表型切换驱动的耐药性
Lorenza P Ferretti1, Flurina Böhi1, Deena M Leslie Pedrioli1
1Department of Molecular Mechanisms of Disease, University of Zurich, Zurich, Switzerland.
Cancer research
|September 20, 2023
概括
PARP 抑制剂 (PARPi) 通过逆转表型切换和诱导细胞死亡,使黑色素瘤对MAPK 抑制剂 (MAPKi) 重新敏感. 这种组合疗法提供了一个有希望的策略,以克服转移性黑色素瘤中获得的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 转移性黑色素瘤通常会对像MAPK抑制剂 (MAPKi) 这样的向疗法产生抗性.
- 现型切换,即过渡到高度侵入性的状态,是驱动这种抗性的关键机制.
- 针对抗性机制对于改善黑色素瘤治疗结果至关重要.
研究的目的:
- 确定治疗策略,以克服黑色素瘤中MAPKi抵抗.
- 为了研究染色体调节器在介导抗性的作用.
- 为了评估PARP抑制剂 (PARPi) 与MAPKis结合的疗效.
主要方法:
- 在3D MAPKi抗性黑色素瘤培养物中对染色体调节者的药物查.
- 综合转录基因,蛋白质基因和表观基因分析.
- 在体外和体内研究使用患者衍生的异种移植模型.
主要成果:
- PARP抑制剂 (PARPi) 恢复了对MAPKis的敏感性,独立于DNA损伤的修复.
- PARPi诱导了溶酶体自细胞死亡和改变了线粒体代谢.
- PARPi逆转了表皮细胞-介质细胞过渡类型的表型切换,促进了繁殖状态.
- 组合疗法在体外和体内协同诱导了癌细胞死亡.
结论:
- 在黑色素瘤中,PARP抑制剂可以克服对MAPK抑制剂的获得性耐药性.
- PARPi和MAPKis的组合提供了一种协同方法来治疗耐药黑色素瘤.
- 这种策略增强了抗原呈现和T细胞细胞毒性,提高了治疗疗效.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


